Evidence map›Paper›PMID 40728766›Full record

ArticleJournal of clinical immunology2025

Molecular Interactions Between NK Cells and Acute Leukemic Cells: KIR2DL5 Drastically Limits NK Cell Responses.

Enora Ferron, Maxime Jullien, Martin Braud, Gaëlle David, Cynthia Fourgeux, Mathilde Bastien, Perla Salameh, Catherine Willem, Nolwenn Legrand, Alexandre Walencik and 8 more

Abstract read
In one paragraph

Article in Journal of clinical immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Enora FerronResearch Laboratory Etablissement Français du Sang, 44011, Nantes, France.
Maxime JullienResearch Laboratory Etablissement Français du Sang, 44011, Nantes, France.
Martin BraudNantes Université,CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, 44000, Nantes, France.
Gaëlle DavidResearch Laboratory Etablissement Français du Sang, 44011, Nantes, France.
Cynthia FourgeuxNantes Université,CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, 44000, Nantes, France.
Mathilde BastienHematology Department, Nantes University Hospital, Nantes, France.
Perla SalamehResearch Laboratory Etablissement Français du Sang, 44011, Nantes, France.
Catherine WillemResearch Laboratory Etablissement Français du Sang, 44011, Nantes, France.
Nolwenn LegrandResearch Laboratory Etablissement Français du Sang, 44011, Nantes, France.
Alexandre WalencikLaboratoire d'histocompatibilité, Etablissement Français du Sang de Centre-Pays de La Loire, 44011, Nantes, France.
Thierry GuillaumeINSERM UMR1307, CNRS UMR 6075, CRCI2NA, Team 12, 44000, Nantes, France.
Pierre PeterlinHematology Department, Nantes University Hospital, Nantes, France.
Alice GarnierHematology Department, Nantes University Hospital, Nantes, France.
Amandine LebourgeoisHematology Department, Nantes University Hospital, Nantes, France.
Katia GagneResearch Laboratory Etablissement Français du Sang, 44011, Nantes, France.
Jeremie PoschmannNantes Université,CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology, UMR 1064, 44000, Nantes, France.
Patrice ChevallierINSERM UMR1307, CNRS UMR 6075, CRCI2NA, Team 12, 44000, Nantes, France.
Christelle RetièreResearch Laboratory Etablissement Français du Sang, 44011, Nantes, France. christelle.retiere@efs.sante.fr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural Killer (NK) cells naturally recognize and eliminate leukemic cells. However, the molecular interactions that govern these responses are diverse due to the large number of activating and inhibitory NK receptors that modulate NK functions and the diversity of corresponding ligands that are differentially expressed in acute lymphoblastic and myeloblastic leukemias. We identified resting NKG2A

Indexed as

Killer Cells, NaturalLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, KIR2DL5Cell CommunicationCytotoxicity, ImmunologicHumansNK Cell Lectin-Like Receptor Subfamily CReceptors, KIRReceptors, KIR2DL1KIR2DL1 protein, humanNK Cell Lectin-Like Receptor Subfamily CReceptors, KIRReceptors, KIR2DL1Receptors, KIR2DL5Acute leukemiaHeterogeneityNK cells

Identifiers

PMID40728766
PMCPMC12307528

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.